Virtual reality will become a new platform for translational medicine to reduce r&d risk and cost

- Nov 07, 2017 -

Virtual reality will become a new platform for translational medicine to reduce r&d risk and cost

vr.jpg

"In the next decade, virtual reality technology will bring unprecedented and disruptive development in the field of life sciences and medicine." Zhao qinping, an academician of the Chinese academy of engineering, asserted at the 17th China virtual reality conference recently. He believes that virtual reality will become a new platform for translational medical research and new experimental methods to promote surgical planning, surgical training, new surgical research and development, and new drug development.


Zhao qinping said, "the development of pathophysiology modeling technology, the development of new software platform and the growth of available data have jointly promoted the new development of bio-simulation technology. The application of the biological simulation preview supports the development of new therapeutic drugs, which will meet the requirements of the pharmaceutical industry to develop new methods for the treatment of difficult and complicated diseases, and reduce the r&d risks and costs resulting from this.


He believes that as VR develops, especially as virtual reality extends to medicine, virtual human beings become a foundation. Physiological model of various scale unit body and the human brain and its intelligent feature model is a virtual human body the ultimate research target, and the need of molecular biology, biophysics, systems biology, brain science, and the common development of artificial intelligence research.


Related Products